miRecule

microRNA Therapeutics for Cancer

MC-DX4 RD facioscapulohumeral muscular dystrophy; undisclosed RD DLBCL

miRecule is developing RNA-based therapies for the treatment of cancer, macular dystrophy, and rare diseases. Using genomic patient data, these therapeutics can be made highly patient and tissue specific. Their platform allows the identification of genetic changes underlying disease and development of targeted therapies to correct the genetic change. This technology is especially useful in genetic disorders. By harnessing the regulatory role of RNA in cellular processes, miRecule aims to develop innovative therapies that offer new treatment options for patients with challenging cancers and rare genetic diseases. Their research-driven approach holds promise for advancing precision medicine through rigorous scientific exploration and therapeutic innovation.